(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 September 2019 (26.09.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/182925 A1

(51) International Patent Classification:
A61K 31/427 (2006.01) *A61P 11/00* (2006.01)
C07D 471/04 (2006.01) *A61P 29/00* (2006.01)
C07D 473/30 (2006.01) *A61P 23/00* (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/US2019/022659

(22) International Filing Date:
18 March 2019 (18.03.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/644,987	19 March 2018 (19.03.2018)	US
62/676,057	24 May 2018 (24.05.2018)	US
62/725,488	31 August 2018 (31.08.2018)	US
62/812,806	01 March 2019 (01.03.2019)	US

(71) Applicant *(for US only)*: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080 (US).

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(72) Inventors: **TERRETT, Jack Alexander**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **CHEN, Huifen**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **CONSTANTINEAU-FORGET, Lea**; c/o Paraza Pharma, Inc., 2525 Marie-Curie Avenue, Montreal, Québec H4S 2E1 (CA). **LAROUCHE-GAUTHIER, Robin**; c/o Paraza Pharma, Inc., 2525 Marie-Curie Avenue, Montreal, Québec H4S 2E1 (CA). **LÉPISSIER, Luce**; c/o Paraza Pharma, Inc., 2525 Marie-Curie Avenue, Montreal, Québec H4S 2E1 (CA). **BEAUMIER, Francis**; c/o Paraza Pharma, Inc., 2525 Marie-Curie Avenue, Montreal, Québec H4S 2E1 (CA). **DÉRY, Martin**; c/o Paraza Pharma, Inc., 2525 Marie-Curie Avenue, Montreal, Québec H4S 2E1 (CA). **GRAND-MAÎTRE, Chantal**; c/o Paraza Pharma, Inc., 2525 Marie-Curie Avenue, Montreal, Québec H4S 2E1 (CA). **STURINO, Claudio**; c/o Paraza Pharma, Inc., 2525 Marie-Curie Avenue, Montreal, Québec H4S 2E1 (CA). **VOLGRAF, Matthew**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **VILLEMURE, Elisia**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US).


(74) Agent: **HALL, Robert C.** et al.; c/o Genentech, Inc., 1 DNA Way, Mail Stop 49, South San Francisco, California 94080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS



(I)

(57) Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1?, R4? and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

WO 2019/182925 A1